Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma

BACKGROUND: The current standard of treatment for advanced hepatocellular cancer Hepatocellular carcinoma (HCC) is Sorafenib. Data regarding its tolerance and adverse event profile in Indian patients is scarce. MATERIALS AND METHODS: The primary aim of this analysis was to assess the adverse events...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:South Asian J Cancer
Hlavní autoři: Ostwal, Vikas, Gupta, Tarachand, Chopra, Supriya, Lewis, Sherly, Goel, Mahesh, Patkar, Shraddha, Shetty, Nitin, Ramaswamy, Anant
Médium: Artigo
Jazyk:Inglês
Vydáno: Medknow Publications & Media Pvt Ltd 2017
Témata:
ORIGINAL ARTICLE: Gastro-intestinal & Hepatobiliary Cancers
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5763620/
https://ncbi.nlm.nih.gov/pubmed/29404288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/sajc.sajc_44_17
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky